Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

85.49 +1.47 (+1.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,501,573
Open	84.77
Bid (Size)	86.00 (100)
Ask (Size)	87.87 (100)
Prev. Close	84.02
Today's Range	84.77 - 88.27
52wk Range	36.36 - 120.74
Shares Outstanding	101,298,669
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Via The Motley Fool

Performance

YTD	-16.0%	-16.0%
1 Month	-20.5%	-20.5%
3 Month	-16.2%	-16.2%
6 Month	+55.7%	+55.7%
1 Year	+110.4%	+110.4%

More News

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗

February 19, 2026

Via Chartmill

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

March 10, 2026

From Guardant Health, Inc.

Via Business Wire

1 Russell 2000 Stock on Our Watchlist and 2 We Question

March 05, 2026

Via StockStory

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

March 04, 2026

From Guardant Health, Inc.

Via Business Wire

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

March 03, 2026

From Guardant Health, Inc.

Via Business Wire

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

February 27, 2026

Via StockStory

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2026

From Guardant Health, Inc.

Via Business Wire

The Great Rotation: Small-Caps Break Record Highs as the 'Catch-Up' Trade Ignites

February 26, 2026

Via MarketMinute

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

Via StockStory

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

February 19, 2026

Via StockStory

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

February 19, 2026

From Guardant Health, Inc.

Via Business Wire

Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

February 17, 2026

Via StockStory

3 Unprofitable Stocks Walking a Fine Line

February 15, 2026

Via StockStory

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

Via MarketMinute

Guardant Health to Participate in Upcoming Investor Conferences

February 03, 2026

From Guardant Health, Inc.

Via Business Wire

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 02, 2026

From Guardant Health, Inc.

Via Business Wire

3 Unpopular Stocks We Think Twice About

February 01, 2026

Via StockStory

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

Via The Motley Fool

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19, 2026

From Guardant Health, Inc.

Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?

Yes, Guardant Health, Inc. - Common Stock is publicly traded.

What exchange does Guardant Health, Inc. - Common Stock trade on?

Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Guardant Health, Inc. - Common Stock?

The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market

What is the current price of Guardant Health, Inc. - Common Stock?

The current price of Guardant Health, Inc. - Common Stock is 85.49

When was Guardant Health, Inc. - Common Stock last traded?

The last trade of Guardant Health, Inc. - Common Stock was at 03/13/26 04:00 PM ET

What is the market capitalization of Guardant Health, Inc. - Common Stock?

The market capitalization of Guardant Health, Inc. - Common Stock is 8.66B

How many shares of Guardant Health, Inc. - Common Stock are outstanding?

Guardant Health, Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.